Press releases

These press releases are intended for business journalists and analysts/investors

Landmark IMPACT study published in NEJM shows significant benefits of Trelegy for high risk patients with COPD

GSK recently announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, providing the evidence that high risk patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation can benefit from Trelegy including inhaled corticosteroids (“ICS”).

Read more - Landmark IMPACT study published in NEJM shows significant benefits of Trelegy for high risk patients with COPD Read more